Lentiviral Vectors for Ocular Gene Therapy
Open accessThe DOI matches its Crossref record; 206 of the 208 references it cites were found in a registry or an index.
Abstract
This review offers the basics of lentiviral vector technologies, their advantages and pitfalls, and an overview of their use in the field of ophthalmology. First, the description of the global challenges encountered to develop safe and efficient lentiviral recombinant vectors for clinical application is provided. The risks and the measures taken to minimize secondary effects as well as new strategies using these vectors are also discussed. This review then focuses on lentiviral vectors specifically designed for ocular therapy and goes over preclinical and clinical studies describing their safety and efficacy. A therapeutic approach using lentiviral vector-mediated gene therapy is currently being developed for many ocular diseases, e.g., aged-related macular degeneration, retinopathy of prematurity, inherited retinal dystrophies (Leber congenital amaurosis type 2, Stargardt disease, Usher syndrome), glaucoma, and corneal fibrosis or engraftment rejection. In summary, this review shows how lentiviral vectors offer an interesting alternative for gene therapy in all ocular compartments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Entry and integration of HIV-1. Structural and enzymatic HIV-1 genes are presented in gray boxes, HIV-1 regulatory factors in green, HIV-1 accessory factors in blue, and LTR in yellow. Corresponding proteins are represented with the same color code in a schematic HIV-1 particle. The different processes, from binding to the cell membrane to the integration of the provirus DNA into the host genome, are depicted with viral protein required at each step. The timing of uncoating of the capsid (CA) and the role of CA is still unclear, as discussed in a recent review [11]. The Gag gene codes for matrix proteins (MA), capsid proteins (CA), and nucleocapsid protein (NC). The Pol gene encodes for the reverse transcriptase (RT), the integrase (IN), and the protease (PRO).](https://figures.cochat.ai/paper-figures/f17286d4d038409bb4bfc035d2358af9/lentiviral-vectors-for-ocular-gene-therapy-figure-1.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, they carry risks for insertional mutagenesis and germline transmission and may elicit more inflammatory responses than AAVs.54,56,73”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–206 of 206
Udry, F., Decembrini, S., Gamm, D. M., Déglon, N., Kostic, C., & Arsenijévic, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-65657-y · Cited by 10 · cited 1×
“Finally, these preclinical data were reinforced by the demonstration that LV can increase the level of RPE65 mRNA in human iPSCs-derived RPE cells [155], strongly supporting the potential of this vector for clinical applications of gene expression in the RPE.”
BackgroundSelf-citationA Rev-Independent gag/pol Eliminates Detectable psi-gag Recombination in Lentiviral Vectors
Tareen, S. U., Nicolai, C. J., Campbell, D. J., Flynn, P. A., Slough, M. M., Vin, C. D., Kelley-Clarke, B., Odegard, J. M., & Robbins, S. H. (2013) · BioResearch Open Access · doi:10.1089/biores.2013.0037 · Cited by 8 · cited 1×
“In addition, other systems were developed to minimize RCLs, such as Rev-independent LV [44] or a five plasmids trans-lentiviral system, which separates the RT-IN from the Gag-Pol [45,46].”
MethodCorre, G., Dessainte, M., Marteau, J., Dalle, B., Fenard, D., & Galy, A. H. M. (2016) · Human Gene Therapy · doi:10.1089/hum.2015.166 · Cited by 7
Saenz, D. T., Barraza, R., Loewen, N. A., Teo, W., & Poeschla, E. M. (2011) · Cold Spring Harbor Protocols · doi:10.1101/pdb.prot067546 · Cited by 7 · cited 1×
“Upscaling was reported with the use of a cell factory [72,73] or Bioreactor [74], sometimes including several transfection adaptations such as the addition of polyethylenimine”
MethodTrabecular Repopulation by Anterior Trabecular Meshwork Cells After Laser Trabeculoplasty: Reply
Acott, T. S., Samples, J. R., Bradley, J. M. B., et al. (1989) · American Journal of Ophthalmology · doi:10.1016/0002-9394(89)90033-0 · Cited by 7
Correction to: Gene therapy knockdown of VEGFR2 in retinal endothelial cells to treat retinopathy
Simmons, A. B., Bretz, C. A., Wang, H., Kunz, E., Hajj, K., Kennedy, C. D., Yang, Z., Suwanmanee, T., Kafri, T., & Hartnett, M. E. (2018) · Angiogenesis · doi:10.1007/s10456-018-9626-5 · Cited by 3 · cited 2×
“To that aim, LV coding for shRNAs against Vegfr2 or Stat3 mRNAs, under the control of the VE-Cadherin promoter, was produced and first validated to downregulate VEGFR2 signaling [145] before being tested in an OIR rat model.”
BackgroundMethod
Cited by
Viral Vector-Based Gene Therapy
Li, X., Le, Y., Zhang, Z., Nian, X., Liu, B., & Yang, X. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24097736 · Cited by 200
Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions
Drag, S., Dotiwala, F., & Upadhyay, A. K. (2023) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.64.7.39 · Cited by 145
The concept of gene therapy for glaucoma: the dream that has not come true yet
Sulak, R., Liu, X., & Smedowski, A. (2024) · Neural Regeneration Research · doi:10.4103/1673-5374.375319 · Cited by 40
“By affecting the outflow in Schlemm’s canal, it leads to the regulation of aqueous humor outflow (Arsenijevic et al., 2022).”
BackgroundGenome Editing, A Superior Therapy for Inherited Retinal Diseases
Yan, A. L., Du, S. W., & Palczewski, K. (2022) · Vision Research · doi:10.1016/j.visres.2023.108192 · Cited by 40
Protein-Based Degraders: From Chemical Biology Tools to Neo-Therapeutics
Ou, L., Setegne, M. T., Elliot, J., Shen, F., & Dassama, L. M. K. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00595 · Cited by 33
Metadata
- Authors
- Arsenijevic, Y., Berger, A., Udry, F., & Kostic, C.
- Affiliations
- Unit Retinal Degeneration and Regeneration, Department of Ophthalmology, University of Lausanne, Jules-Gonin Eye Hospital, Fondation Asile des Aveugles, 1004 Lausanne, Switzerland
- Fondation Asile des Aveugles (CH)
- Hôpital Ophtalmique Jules-Gonin (CH)
- Corresponding author
- Kostic, Corinne
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2022-07-31
- Volume
- 14
- Issue
- 8
- Pages
- 1605
- ISSN
- 1999-4923 (ISSN-L)
- PMC
- PMC9414879
- OpenAlex
- W4289203946
- Cited by
- 47
- References
- 208
- Citations by year
- 2026: 6 · 2025: 19 · 2024: 12 · 2023: 8 · 2022: 2
- FWCI
- 1.58
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Pharmaceutics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, cc-by)
- IRIS (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Fondation Asile des Aveugles (.)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- lentiviral vectors, ocular gene therapy, age-related macular degeneration, retinopathy of prematurity, inherited retinal disease, Stargardt disease, Usher syndrome, glaucoma, corneal fibrosis, preclinical and clinical studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.